2 型糖尿病患者的 C 肽微不均一性。
C-peptide microheterogeneity in type 2 diabetes populations.
机构信息
The Biodesign Institute at Arizona State University, Tempe, 85287, USA.
出版信息
Proteomics Clin Appl. 2010 Jan;4(1):106-11. doi: 10.1002/prca.200800249. Epub 2009 Nov 11.
Abstract
PURPOSE
The purpose of this study was to investigate naturally occurring C-peptide microheterogeneity in healthy and type 2 diabetes (T2D) populations.
EXPERIMENTAL DESIGN
MS immunoassays capable of simultaneously detecting intact C-peptide and variant forms were applied to plasma samples from 48 healthy individuals and 48 individuals diagnosed with T2D.
RESULTS
Common throughout the entire sample set were three previously unreported variations of C-peptide. The relative contribution of one variant, subsequently identified as C-peptide (3-31), was found to be more abundant in the T2D population as compared to the healthy population. Dipeptidyl peptidase IV is suspected to be responsible for this particular cleavage product, which is consistent with the pathophysiology of T2D.
CONCLUSIONS AND CLINICAL RELEVANCE
C-peptide does not exist in the human body as a single molecular species. It is qualitatively more heterogeneous than previously thought. These results lay a foundation for future studies devoted to a comprehensive understanding of C-peptide and its variants in healthy and diabetic populations.
摘要
目的
本研究旨在调查健康人群和 2 型糖尿病（T2D）人群中天然存在的 C 肽的微观异质性。
实验设计
应用能够同时检测完整 C 肽和变异形式的 MS 免疫分析方法，对 48 名健康个体和 48 名被诊断为 T2D 的个体的血浆样本进行了检测。
结果
在整个样本集中，共发现了三种以前未报道过的 C 肽变异体。与健康人群相比，T2D 人群中一种名为 C 肽（3-31）的变异体的相对丰度更高。推测二肽基肽酶 IV 负责这种特定的裂解产物，这与 T2D 的病理生理学相一致。
结论和临床意义
C 肽在人体内并不存在单一的分子种类。它比之前认为的更具异质性。这些结果为未来致力于全面了解健康人群和糖尿病患者的 C 肽及其变体的研究奠定了基础。
相似文献
1
C-peptide microheterogeneity in type 2 diabetes populations.2 型糖尿病患者的 C 肽微不均一性。
Proteomics Clin Appl. 2010 Jan;4(1):106-11. doi: 10.1002/prca.200800249. Epub 2009 Nov 11.
2
Mass spectrometric characterization and activity of zinc-activated proinsulin C-peptide and C-peptide mutants.锌离子激活的胰岛素原 C 肽及其突变体的质谱特征分析和活性研究。
Analyst. 2010 Feb;135(2):278-88. doi: 10.1039/b917600d. Epub 2009 Dec 4.
3
Proteomics-based identification of differentially-expressed proteins including galectin-1 in the blood plasma of type 2 diabetic patients.基于蛋白质组学鉴定2型糖尿病患者血浆中包括半乳糖凝集素-1在内的差异表达蛋白。
J Proteome Res. 2009 Mar;8(3):1255-62. doi: 10.1021/pr800850a.
4
N-terminal segment of proinsulin C-peptide active in insulin interaction/desaggregation.胰岛素相互作用/解聚中具有活性的胰岛素原 C 肽 N 端片段。
Biochem Biophys Res Commun. 2010 Dec 17;403(3-4):462-7. doi: 10.1016/j.bbrc.2010.11.058. Epub 2010 Nov 19.
5
Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.成人隐匿性自身免疫性糖尿病的管理：国际专家小组的共识声明。
Diabetes. 2020 Oct;69(10):2037-2047. doi: 10.2337/dbi20-0017. Epub 2020 Aug 26.
6
The entero-insular axis: implications for human metabolism.肠-胰岛轴：对人体新陈代谢的影响。
Clin Chem Lab Med. 2008;46(1):43-56. doi: 10.1515/CCLM.2008.008.
7
Estimated proinsulin processing activity of prohormone convertase (PC) 1/3 rather than PC2 is decreased in pancreatic β-cells of type 2 diabetic patients.在2型糖尿病患者的胰腺β细胞中，激素原转化酶（PC）1/3而非PC2的胰岛素原加工活性估计有所降低。
Endocr J. 2014;61(6):607-14. doi: 10.1507/endocrj.ej13-0506. Epub 2014 Apr 5.
8
Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism.胰抑制素：对人体体内中间代谢的多种作用、疾病中的变化以及自然发生的功能性基因多态性。
J Clin Endocrinol Metab. 2005 Sep;90(9):5414-25. doi: 10.1210/jc.2005-0408. Epub 2005 Jun 14.
9
Microheterogeneity of human filaggrin: analysis of a complex peptide mixture using mass spectrometry.人丝聚合蛋白的微观异质性：利用质谱分析法分析复杂肽混合物
Protein Sci. 1996 Jun;5(6):1157-64. doi: 10.1002/pro.5560050618.
引用本文的文献
1
Human C-peptide Quantitation by LC-MS Isotope-Dilution Assay in Serum or Urine Samples.采用液相色谱-质谱同位素稀释法对血清或尿液样本中的人C肽进行定量分析。
J Chromatogr Sep Tech. 2013;4(3). doi: 10.4172/2157-7064.1000172. Epub 2013 Mar 27.
2
Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.质谱免疫分析在临床重要蛋白质变体表征中的应用
Proteomes. 2016 Mar 17;4(1):13. doi: 10.3390/proteomes4010013.
3
Isotope dilution assay in peptide quantification: the challenge of microheterogeneity of internal standard.肽定量的同位素稀释分析：内标微不均一性的挑战。
Proteomics Clin Appl. 2013 Dec;7(11-12):825-8. doi: 10.1002/prca.201200130. Epub 2013 Oct 18.
4
Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes.质谱免疫分析和 MRM 作为基于 MS 的靶向定量方法在生物标志物开发中的应用：在心血管疾病和糖尿病中的潜在应用。
Proteomics Clin Appl. 2013 Aug;7(7-8):528-40. doi: 10.1002/prca.201200028. Epub 2013 Jul 9.
5
Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.快速发展的灵敏、高通量、定量且高度选择性的质谱靶向免疫分析方法，用于检测人血浆和血清中的临床重要蛋白。
Clin Biochem. 2013 Apr;46(6):399-410. doi: 10.1016/j.clinbiochem.2012.12.019. Epub 2013 Jan 8.
6
Mass spectrometric immunoassay revisited.重新审视质谱免疫测定。
J Am Soc Mass Spectrom. 2011 Jun;22(6):960-8. doi: 10.1007/s13361-011-0094-z. Epub 2011 Mar 8.
7
Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification.用于肽和蛋白质定量的肽免疫亲和富集与质谱联用技术。
Clin Lab Med. 2011 Sep;31(3):385-96. doi: 10.1016/j.cll.2011.07.004.
8
Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies.用于人群蛋白质组学研究的完整胰岛素及相关变异体的质谱免疫分析。
Proteomics Clin Appl. 2011 Aug;5(7-8):454-9. doi: 10.1002/prca.201000112. Epub 2011 Jun 8.
9
Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity.基于蛋白质微异质性构建 2 型糖尿病的多维生物标志物视图。
Clin Chem. 2011 May;57(5):719-28. doi: 10.1373/clinchem.2010.156976. Epub 2011 Mar 14.
本文引用的文献
1
Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure.心力衰竭患者极低浓度内源性B型利钠肽的检测
Circ Heart Fail. 2008 Nov;1(4):258-64. doi: 10.1161/CIRCHEARTFAILURE.108.790774. Epub 2008 Oct 14.
2
Standardization of C-peptide measurements.C肽测量的标准化
Clin Chem. 2008 Jun;54(6):1023-6. doi: 10.1373/clinchem.2007.101287. Epub 2008 Apr 17.
3
Feasibility of standardization of serum C-peptide immunoassays with isotope-dilution liquid chromatography-tandem mass spectrometry.采用同位素稀释液相色谱-串联质谱法对血清C肽免疫分析进行标准化的可行性
Clin Chem. 2006 Jun;52(6):1193-6. doi: 10.1373/clinchem.2005.062505. Epub 2006 Apr 13.
4
Sensitive quantitative analysis of C-peptide in human plasma by 2-dimensional liquid chromatography-mass spectrometry isotope-dilution assay.二维液相色谱-质谱同位素稀释法对人血浆中C肽的灵敏定量分析。
Clin Chem. 2006 May;52(5):872-9. doi: 10.1373/clinchem.2005.063081. Epub 2006 Mar 23.
5
Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.二肽基肽酶IV抑制剂在糖尿病中的应用。
Int J Biochem Cell Biol. 2006;38(5-6):860-72. doi: 10.1016/j.biocel.2005.12.013. Epub 2006 Jan 11.
6
Improvement of sample pretreatment prior to analysis of C-peptide in serum by isotope-dilution liquid chromatography/tandem mass spectrometry.通过同位素稀释液相色谱/串联质谱法分析血清中C肽之前，改进样品预处理方法。
Rapid Commun Mass Spectrom. 2005;19(23):3600-2. doi: 10.1002/rcm.2215.
7
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.高血糖会增加糖尿病患者体内二肽基肽酶IV的活性。
Diabetologia. 2005 Jun;48(6):1168-72. doi: 10.1007/s00125-005-1749-8. Epub 2005 Apr 29.
8
Glucagon-like peptide 1(GLP-1) in biology and pathology.生物学和病理学中的胰高血糖素样肽1（GLP-1）
Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):91-117. doi: 10.1002/dmrr.538.
9
Collision-induced dissociation of the [M-2H]2- ion of C-peptide.C肽的[M - 2H]²⁻离子的碰撞诱导解离
Rapid Commun Mass Spectrom. 2004;18(24):3140-1. doi: 10.1002/rcm.1716.
10
C-peptide: much more than a byproduct of insulin biosynthesis.C肽：远不止是胰岛素生物合成的副产物。
Pancreas. 2004 Oct;29(3):231-8. doi: 10.1097/00006676-200410000-00009.
Zotero 插件